Amgen's biologic drugs treat diseases rooted in human biology - AGI cannot cure cancer with software, and AI actually accelerates Amgen's drug discovery capabilities.
Amgen is one of the world's largest biotechnology companies, focused on discovering, developing, manufacturing, and commercializing innovative human therapeutics. The company has a broad portfolio of medicines treating serious diseases including oncology, cardiovascular disease, bone health, inflammation, and rare diseases. Amgen is a pioneer in biologics manufacturing and has expanded into biosimilars. The 2023 acquisition of Horizon Therapeutics for $28 billion added rare disease and inflammation drugs to its portfolio.
Amgen sells its products to wholesale distributors (AmerisourceBergen, McKesson, Cardinal Health account for a large share), hospitals, pharmacies, and healthcare providers. End users are patients with serious chronic and acute diseases. Amgen also partners with other pharmaceutical companies on co-development (e.g., AstraZeneca for TEZSPIRE). Government payers (Medicare, Medicaid) and commercial insurers are key payers.
Amgen develops and manufactures biologic drugs - large, complex protein-based medicines for serious diseases including cancer, cardiovascular disease, bone disorders, and inflammation. AGI cannot replace physical drug molecules. Products like Repatha, Prolia/Xgeva, Enbrel, Lumakras, and MariTide are physical therapeutics that must be manufactured in bioreactors and administered to patients. Amgen's customers are patients with serious diseases, hospitals, healthcare systems, and pharmacies. Sick patients need medicine regardless of AGI. The healthcare system serves biological needs that AI cannot eliminate.